doi: 10.3389/fnut.2022.1007816 Received 31 July 2022 Accepted 12 October 2022 Published 01 November 2022 Volume 9 - 2022 Edited by Yannan Jin, De Montfort University, United Kingdom Reviewed by Mostafa Waly, Sultan Qaboos University, Oman
It also calls for baseline labs covering fasting glucose, creatinine and eGFR, liver enzymes, a lipid panel and electrolytes, with follow-up roughly every three months, because sustained high protein intake alongside GLP-1 therapy can move kidney markers in susceptible people
Patent-pending status indicates active intellectual property protection and significant R&D investment behind the ingredient combinations
The bulk of this evidence is pre-clinical
We just released our new CLA and L-Carnitine supps
August 18, 2025: Ozempic Lawsuits Will Move Forward Against Novo Nordisk Judge Karen M